文献

J-GLOBAL ID：202202240908160501   整理番号：22A1091042

アンギオテンシン変換酵素阻害剤の使用は前立腺癌に対する放射線療法後の遅発性膀胱毒性のリスク低下と関連する【JST・京大機械翻訳】

Use of angiotensin converting enzyme inhibitors is associated with reduced risk of late bladder toxicity following radiotherapy for prostate cancer

著者 (59件)： Kerns Sarah L. (Department of Radiation Oncology, University of Rochester Medical Center, Rochester, United States) ,  Amidon Morlang Ashley (Department of Radiation Oncology, University of Rochester Medical Center, Rochester, United States) ,  Lee Sharon M. (Department of Radiation Oncology, University of Rochester Medical Center, Rochester, United States) ,  Peterson Derick R. (Department of Biostatistics and Computational Biology, University of Rochester Medical Center, Rochester, United States) ,  Marples Brian (Department of Radiation Oncology, University of Rochester Medical Center, Rochester, United States) ,  Zhang Hong (Department of Radiation Oncology, University of Rochester Medical Center, Rochester, United States) ,  Bylund Kevin (Department of Radiation Oncology, University of Rochester Medical Center, Rochester, United States) ,  Rosenzweig Doug (Department of Radiation Oncology, University of Rochester Medical Center, Rochester, United States) ,  Hall William (Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, United States) ,  De Ruyck Kim (Department of Radiation Oncology, Ghent University Hospital and Department of Human Structure and Repair, Ghent University, Ghent, Belgium) ,  Rosenstein Barry S. (Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, United States) ,  Rosenstein Barry S. (Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, United States) ,  Stock Richard G. (Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, United States) ,  Gomez-Caamano Antonio (Department of Radiation Oncology, Complexo Hospitalario Universitario de Santiago, SERGAS, Santiago de Compostela, Spain) ,  Gomez-Caamano Antonio (Instituto de Investigacion Sanitaria de Santiago de Compostela (IDIS), Santiago de Compostela, Spain) ,  Vega Ana (Instituto de Investigacion Sanitaria de Santiago de Compostela (IDIS), Santiago de Compostela, Spain) ,  Vega Ana (Fundacion Publica Galega de Medicina Xenomica-Servizo Galego de Saude (SERGAS), Santiago de Compostela, Spain) ,  Vega Ana (Centro de Investigacion Biomedica en Red de Enfermedades Raras (CIBERER), Santiago de Compostela, Spain) ,  Sosa-Fajardo Paloma (Department of Radiation Oncology, Complexo Hospitalario Universitario de Santiago, SERGAS, Santiago de Compostela, Spain) ,  Sosa-Fajardo Paloma (Instituto de Investigacion Sanitaria de Santiago de Compostela (IDIS), Santiago de Compostela, Spain) ,  Sosa-Fajardo Paloma (Fundacion Publica Galega de Medicina Xenomica-Servizo Galego de Saude (SERGAS), Santiago de Compostela, Spain) ,  Taboada-Valladares Begona (Department of Radiation Oncology, Complexo Hospitalario Universitario de Santiago, SERGAS, Santiago de Compostela, Spain) ,  Taboada-Valladares Begona (Instituto de Investigacion Sanitaria de Santiago de Compostela (IDIS), Santiago de Compostela, Spain) ,  Aguado-Barrera Miguel E. (Instituto de Investigacion Sanitaria de Santiago de Compostela (IDIS), Santiago de Compostela, Spain) ,  Aguado-Barrera Miguel E. (Fundacion Publica Galega de Medicina Xenomica-Servizo Galego de Saude (SERGAS), Santiago de Compostela, Spain) ,  Parker Chris (Department of Uro-oncology, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Sutton, United Kingdom) ,  Veldeman Liv (Department of Radiation Oncology, Ghent University Hospital and Department of Human Structure and Repair, Ghent University, Ghent, Belgium) ,  Fonteyne Valerie (Department of Radiation Oncology, Ghent University Hospital and Department of Human Structure and Repair, Ghent University, Ghent, Belgium) ,  Bultijnck Renee (Department of Radiation Oncology, Ghent University Hospital and Department of Human Structure and Repair, Ghent University, Ghent, Belgium) ,  Talbot Christopher J. (Leicester Cancer Research Centre, University of Leicester, United Kingdom) ,  Symonds R. Paul (Leicester Cancer Research Centre, University of Leicester, United Kingdom) ,  Johnson Kerstie (Leicester Cancer Research Centre, University of Leicester, United Kingdom) ,  Rattay Tim (Leicester Cancer Research Centre, University of Leicester, United Kingdom) ,  Webb Adam (Department of Genetics and Genome Biology, University of Leicester, United Kingdom) ,  Lambrecht Maarten (KU Leuven, Radiation Oncology, Leuven, Belgium) ,  de Ruysscher Dirk (KU Leuven, Radiation Oncology, Leuven, Belgium) ,  de Ruysscher Dirk (Maastricht University Medical Center, Department of Radiation Oncology (Maastro Clinic), GROW School for Oncology and Developmental Biology, Maastricht, the Netherlands) ,  Vanneste Ben (KU Leuven, Radiation Oncology, Leuven, Belgium) ,  Vanneste Ben (Maastricht University Medical Center, Department of Radiation Oncology (Maastro Clinic), GROW School for Oncology and Developmental Biology, Maastricht, the Netherlands) ,  Choudhury Ananya (Division of Cancer Sciences, the University of Manchester, Manchester Academic Health Science Centre, Christie Hospital, Manchester, the Netherlands) ,  Elliott Rebecca M. (Division of Cancer Sciences, the University of Manchester, Manchester Academic Health Science Centre, Christie Hospital, Manchester, the Netherlands) ,  Sperk Elena (Department of Radiation Oncology, Universitaetsmedizin Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany) ,  Herskind Carsten (Department of Radiation Oncology, Universitaetsmedizin Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany) ,  Veldwijk Marlon R. (Department of Radiation Oncology, Universitaetsmedizin Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany) ,  Rancati Tiziana (Prostate Cancer Program, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy) ,  Avuzzi Barbara (Department of Radiation Oncology 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy) ,  Valdagni Riccardo (Prostate Cancer Program, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy) ,  Valdagni Riccardo (Department of Radiation Oncology 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy) ,  Valdagni Riccardo (Department of Oncology and Hemato-oncology, Universita degli Studi di Milano, Milan, Italy) ,  Azria David (Department of Radiation Oncology, Montpellier Cancer Institute, Universite Montpellier, Inserm U1194, France) ,  Farcy Jacquet Marie-Pierre (ICG Cancer Institute, Centre Hospitalier Universitaire de Nimes, Nimes, France) ,  Chang-Claude Jenny (Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany) ,  Chang-Claude Jenny (Cancer Epidemiology Group, University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Germany) ,  Seibold Petra (Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany) ,  West Catharine (Division of Cancer Sciences, the University of Manchester, Manchester Academic Health Science Centre, Christie Hospital, Manchester, the Netherlands) ,  Janelsins Michelle (Department of Surgery, University of Rochester Medical Center, Rochester, United States) ,  Chen Yuhchyau (Department of Radiation Oncology, University of Rochester Medical Center, Rochester, United States) ,  Messing Edward (Department of Urology, University of Rochester Medical Center, Rochester, United States) ,  Morrow Gary (Department of Surgery, University of Rochester Medical Center, Rochester, United States)
資料名： Radiotherapy and Oncology  (Radiotherapy and Oncology)
巻： 168  ページ： 75-82  発行年： 2022年 
JST資料番号： W3151A  ISSN： 0167-8140  資料種別： 逐次刊行物 (A)
記事区分： 原著論文  発行国： オランダ (NLD)  言語： 英語 (EN)

抄録/ポイント： 前立腺癌放射線療法後の後期血尿のゲノムワイド関連研究(GWAS)は,AGT近くの単一ヌクレオチド多型(SNP)を同定し,アンジオテンシン産生遺伝子をコードする。アンギオテンシン変換酵素阻害剤(ACEi)を服用する患者は,後期血尿のリスク低下を有するという仮説を検証した。さらに,遺伝的に定義された高血圧を試験した。2つの多施設観察研究,URWCI(N=256)およびREQUITE(N=1,437)に,潜在的治療放射線療法を受ける前立腺癌患者を登録した。患者を前放射線療法で評価し,4年間まで毒性の発生を前向きに追跡した。血尿の累積確率をKaplan-Meier法により推定した。多変数グループ化相対リスクモデルは,臨床因子に対して調整する血尿に対するACEiの影響を評価し,登録部位により層化した。血圧に対する多遺伝子リスクスコア(PRS)を,REQUITEにおける血尿との関連および著者らのラジオゲノミクスコンソーシアムGWASで試験した。放射線療法中にACEiを服用した患者は,以前の経尿道前立腺および/または膀胱切除,心臓疾患,骨盤結節放射線療法,および血尿と関連する70Gyを受ける膀胱容積の調整後,血尿のリスク低下(HR 0.51,95%CI 0.28から0.94,p=0.030)を示した。血圧PRSは高血圧と関連していた(標準偏差1.38,95%CI 1.31から1.46,n=5,288,p<0.001)が,血尿ではなかった(標準偏差0.96,95%CI0.87から1.06,n=5,126,p=0.41)。本研究は,骨盤放射線療法を受けている患者の国際的,マルチサイト研究における膀胱に対するACEiの放射線防護効果を初めて示すものである。アンギオテンシン経路の標的化が膀胱をどのように保護するかを理解するためには,機構研究が必要である。Copyright 2022 Elsevier B.V., Amsterdam. All rights reserved. Translated from English into Japanese by JST.【JST・京大機械翻訳】

シソーラス用語： 標準偏差 ,  血圧 ,  遺伝 ,  遺伝子 ,  高血圧症 ,  骨盤 ,  *前立腺 ,  *膀胱 ,  *放射線療法 ,  患者 ,  血尿 ,  *前立腺腫瘍 ,  膀胱切除 ,  一塩基多型 ,  ゲノムワイド関連解析

分類 (2件)： 腫ようの放射線療法  (GE03034K) ,  泌尿生殖器の腫よう  (GM04000S)

タイトルに関連する用語 (7件)： アンギオテンシン変換酵素阻害剤 ,  前立腺癌 ,  放射線療法 ,  遅発性 ,  膀胱 ,  毒性 ,  リスク低下